Corey Fishman
CEO and Founder of Iterum Therapeutics
Articles
SURE1 and REASSURE Trials Paved Way for FDA Approval of Orlynvah
October 30th 2024Corey Fishman and Steven Aronin, MD, discussed trial highlights of Orlynvah for uncomplicated urinary tract infections and outlining plans to seek partners for a market launch to address antibiotic resistance and enhance patient treatment options.
Read More
FDA Approves Oral Sulopenem (Orlynvah) for Uncomplicated Urinary Tract Infections
Published: October 29th 2024 | Updated: October 29th 2024Iterum Therapeutics receives approval for Orlynvah as the first oral penem for treating uncomplicated urinary tract infections in adult women with limited treatment options.
Read More
Latest Updated Articles
Published: August 27th 2024 | Updated: August 28th 2024
Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
Published: March 9th 2022 | Updated: December 21st 2024
Effects of Switching Antibiotics Mid-Treatment on Antimicrobial Resistance
Published: December 5th 2024 | Updated: December 21st 2024
COVID-19 Therapy Roundtable: What is the Virus Today, Treatment Options, and Addressing the Pediatric Population
Published: December 19th 2024 | Updated: December 21st 2024
COVID-19 Roundtable: Should Clinicians Consider Off Label COVID Therapies?
Published: December 17th 2024 | Updated: December 21st 2024
Peer-Assisted Telemedicine Enables More People With Hepatitis C to Get into the Continuum of Care
Published: December 18th 2024 | Updated: December 21st 2024
Ethical and Innovative Use of AI in Infectious Disease
